HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Issue 8 (August 2015)

• Record Type: Journal Article
• Authors: Lee, Jae Hyung; Lee, Won Ki
• Is Part Of: Retina. Volume 35:Issue 8(2015:Aug.)
• Publication Date: 2015-08
• Subjects: Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000000498
• Languages: English
• ISSNs: 0275-004X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Purpose:</title> <p>To evaluate the efficacy of half-dose photodynamic therapy (PDT) combined with intravitreal bevacizumab (IVB) for polypoidal choroidal vasculopathy.</p> </sec> <sec> <title>Methods:</title> <p>For this retrospective comparative study, data from 57 patients (63 eyes) with at least 12 months of follow-up were reviewed. Full-dose or half-dose PDT combined with a single IVB treatment was performed according to the time period. From 3 months after the initial combination treatment, retreatment was performed mainly using anti-vascular endothelial growth factor injections on an as-needed basis.</p> </sec> <sec> <title>Results:</title> <p>Consecutively, 33 eyes were treated with full-dose PDT/IVB and 30 eyes with half-dose PDT/IVB. At Month 3, half-dose PDT/IVB induced negligible damage to the physiologic choroid but was inferior to full-dose PDT/IVB in achieving complete polyp closure (43.3% vs. 72.7%, <italic>P</italic> = 0.018) and improving mean best-corrected visual acuity (20/66 vs. 20/43, <italic>P</italic> = 0.020). At Month 12, the half-dose group achieved comparable visual improvement (20/51 vs. 20/40, <italic>P</italic> = 0.254) but required more additional injections (a mean of 2.80 vs. 1.03, <italic>P</italic> = 0.004).</p> </sec> <sec> <title>Conclusion:</title> <p>Despite inferior efficacy in inducing polyp closure, half-dose PDT/IVB followed by additional injections showed promising visual outcomes while avoiding damage to the physiologic choroid. Further long-term study is needed to evaluate the efficacy of half-dose PDT plus anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.</p> </sec> </abstract>